About lucid diagnostics inc - LUCD
Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company was founded by Lishan Aklog on May 8, 2018 and is headquartered in New York, NY.
LUCD At a Glance
Lucid Diagnostics, Inc.
360 Madison Avenue
New York, New York 10017
| Phone | 1-917-813-1828 | Revenue | 4.71M | |
| Industry | Medical Specialties | Net Income | -58,010,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 8.283% | |
| Fiscal Year-end | 12 / 2026 | Employees | 82 | |
| View SEC Filings |
LUCD Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 23.613 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.209 |
| Enterprise Value to Sales | 33.258 |
| Total Debt to Enterprise Value | 0.165 |
LUCD Efficiency
| Revenue/Employee | 57,390.244 |
| Income Per Employee | -707,439.024 |
| Receivables Turnover | 7.319 |
| Total Asset Turnover | 0.132 |
LUCD Liquidity
| Current Ratio | 1.311 |
| Quick Ratio | 1.286 |
| Cash Ratio | 1.214 |
LUCD Profitability
| Gross Margin | -60.263 |
| Operating Margin | -1,054.824 |
| Pretax Margin | -1,232.682 |
| Net Margin | -1,232.682 |
| Return on Assets | -163.041 |
| Return on Equity | -710.602 |
| Return on Total Capital | -157.825 |
| Return on Invested Capital | -608.901 |
LUCD Capital Structure
| Total Debt to Total Equity | 236.101 |
| Total Debt to Total Capital | 70.247 |
| Total Debt to Total Assets | 63.84 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 2.522 |